
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
PMs find new ground for reinforcing marketing messages and targeting the media mix.
over 25 years ago
Market Research 101over 25 years ago
World-Class Marketing Plansover 25 years ago
How to Win Friends and Influence R&Dover 25 years ago
Working with an Agencyover 25 years ago
A Strategic Overviewover 25 years ago
The Regulatory Environment





